Asia-Pacific dermatology drugs market is projected to register a CAGR of 10.5% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
Asia-Pacific Dermatology Drugs Market By Drug Class (Corticosteroids, Retinoids, Monoclonal Antibodies, Antibiotics Agent, Antiviral Agents, Antifungal Drugs, Antihistamines Agents, Immunosuppressive Drugs, Others), Drug Type (Branded, Generics), Indication (Infectious Skin Disease, Inflammatory/Autoimmune Disorders, Pigmentation Disorders, Skin Cancer, Others), Prescription Mode (Prescription Based Drugs, Over-The-Counter Drugs), Route of Administration (Oral, Topical, Parenteral), End User (Homecare Healthcare, Hospitals, Dermatology Clinics, Others), Distribution Channel (Retail Pharmacy, Hospitals Pharmacy, Online Pharmacy, Others), Country (Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific) Industry Trends & Forecast to 2027
Some of the major factors contributing to the growth of the Asia-Pacific dermatology drugs market are:
• Increasing prevalence of skin diseases
• Rising spending on healthcare
Market Players:
The key market players for Asia-Pacific dermatology drugs market are listed below:
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company.
• Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.)
• Almirall, S.A
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• UCB S.A., Belgium
• Glenmark Pharmaceuticals Limited
• GlaxoSmithKline plc.
• Galderma Laboratories, L.P
• Teva Pharmaceutical Industries Ltd.
• LEO Pharma A/S
• Mayne Pharma Group Limited
• AbbVie Inc.
• Cipla Inc
• Vibcare Pharma Pvt. Ltd
• Ciaga